Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

Abstract

The metabolism of irinotecan (CPT-11) involves sequential activation to SN-38 and detoxification to the pharmacologically inactive SN-38 glucuronide (SN-38G). We have previously demonstrated the role of UGT1A1 enzyme in the glucuronidation of SN-38 and a significant correlation between in vitro glucuronidation of SN-38 and UGT1A1 gene promoter polymorphism. This polymorphism (UGT1A1*28) is characterized by the presence of an additional TA repeat in the TATA sequence of the UGT1A1 promoter, ((TA)7TAA, instead of (TA)6TAA). Here we report the results from a prospective clinical pharmacogenetic study to determine the significance of UGT1A1*28 polymorphism on irinotecan disposition and toxicity in patients with cancer. Twenty patients with solid tumors were treated with a 90 min i.v. infusion of irinotecan (300 mg m−2) once every 3 weeks. The frequency of UGT1A1 genotypes was as follows: 6/6—45%, 6/7—35% and 7/7—20%, with allele frequencies of 0.375 and 0.625 for (TA)7TAA and (TA)6TAA, respectively. Patients with the (TA)7TAA polymorphism had significantly lower SN-38 glucuronidation rates than those with the normal allele (6/6>6/7>7/7, P = 0.001). More severe grades of diarrhea and neutropenia were observed only in patients heterozygous (grade 4 diarrhea, n = 1) or homozygous (grade 3 diarrhea/grade 4 neutropenia, n = 1 and grade 3 neutropenia, n = 1) for the (TA)7TAA sequence. The results suggest that screening for UGT1A1*28 polymorphism may identify patients with lower SN-38 glucuronidation rates and greater susceptibility to irinotecan induced gastrointestinal and bone marrow toxicity.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ et al . Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 2000 343: 905–914

    Article  CAS  PubMed  Google Scholar 

  2. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR et al . Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes J Clin Invest 1998 101: 847–854

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ . Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea Cancer Res 1994 54: 3723–3725

    CAS  PubMed  Google Scholar 

  4. Crigler JF, Najjar . Congenital familial nonhemolytic jaundice with kernicterus Pediatrics 1952 10: 169–180

    PubMed  Google Scholar 

  5. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, Boer A, Oostra BA . The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome N Engl J Med 1995 333: 1171–1175

    Article  CAS  PubMed  Google Scholar 

  6. Iyer L, Hall D, Das S, Mortell MA, Ramirez J, Kim S et al . Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism Clin Pharmacol Ther 1999 65: 576–582

    Article  CAS  PubMed  Google Scholar 

  7. Beutler E, Gelbart T, Demina A . Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998 95: 8170–8174

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B . Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome Lancet 1996 347: 578–581

    Article  CAS  PubMed  Google Scholar 

  9. Hall D, Ybazeta G, Destro-Bisol G, Petzl-Erler ML, Di Rienzo A . Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates Pharmacogenetics 1999 9: 591–599

    Article  CAS  PubMed  Google Scholar 

  10. Takasuna K, Kasai Y, Kitano Y, Mori K, Kakihata K, Hirohashi M et al . Study on the mechanisms of diarrhea induced by the new anticancer drug irinotecan hydrochloride (CPT-11) Folia Pharmacol Jpn 1995 105: 447–460

    Article  CAS  Google Scholar 

  11. Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, Vokes EE et al . Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients J Clin Oncol 1997 15: 1502–1510

    Article  CAS  PubMed  Google Scholar 

  12. Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M . Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports Ann Oncol 1997 8: 1049–1051

    Article  CAS  PubMed  Google Scholar 

  13. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T . UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan Annals Oncol 1998 9: 845–847

    Article  CAS  Google Scholar 

  14. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H et al . Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis Cancer Res 2000 60: 6921–6926

    CAS  PubMed  Google Scholar 

  15. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL . Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer (letter) New Eng J Med 2001 345: 144–145

    Article  CAS  PubMed  Google Scholar 

  16. Huang CS, Luo GA, Huang ML, Yu SC, Yang SS . Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese Pharmacogenetics 2000 10: 539–544

    Article  CAS  PubMed  Google Scholar 

  17. Akaba K, Kimura T, Sasaki A, Tanabe S, Wakabayashi T, Hiroi M et al . Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese J Hum Genet 1 999 44: 22–25

    Article  CAS  Google Scholar 

  18. Akaba K, Kimura T, Sasaki A, Tanabe S, Ikegami T, Hashimoto M et al . Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese Biochem Mol Biol Int 1998 46: 21–26

    CAS  PubMed  Google Scholar 

  19. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al . Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 2001 27: 383–391

    Article  CAS  PubMed  Google Scholar 

  20. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A et al . Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo Proc Natl Acad Sci U S A 2000 97: 3473–3478

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Iyer L, Ramirez J, Shepard DR, Hossfeld D-K, Ratain MJ, Mayer U . Role of p-glycoprotein (Pgp) in biliary excretion of irinotecan (CPT-11) in normal and mdr1a/1b(−/−) mice Drug Metab Rev 2000 32: 196 (Abst)

    Google Scholar 

  22. Pitot HC, Goldberg RM, Reid JM, Sloan JA, Skaff PA, Erlichman C et al . Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy Clin Cancer Res 2000 6: 2236–2244

    CAS  PubMed  Google Scholar 

  23. Cuzick J . A Wilcoxon-type test for trend Statistics in Medicine 1985 4: 87–90

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Supported by grants GM61393, CA69852–07 and RR00055.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M J Ratain.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iyer, L., Das, S., Janisch, L. et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2, 43–47 (2002). https://doi.org/10.1038/sj.tpj.6500072

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500072

Keywords

This article is cited by

Search

Quick links